GlobalDatas report, Growth Hormone Deficiency Pipeline Assessment and Market Forecasts to 2017, is an essential source of information and analysis on the global groeth hormone deficiency (GHD) market. The report identifies the key trends shaping and driving the global GHD market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global Growth Hormone Deficiency segment.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

View Full Report at http://www.marketresearchreports.biz/analysis/29579

GlobalDatas analysis suggests that the global Growth Hormone Deficiency (GHD) therapeutics market was worth $2.7 billion in 2009. The market is expected to grow by a CAGR (Compound Annual Growth Rate) of 2.78% during the next eight years, to reach $3.4 billion by 2017. The GHD market has been well served by synthetic growth hormone (GH), GH regulators and GH secretagogues. The major marketed products for GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin. These are indicated for the treatment of GHD in adults and children and have an average efficacy of about 80% (overall, considering the high efficacy in children and moderate efficacy in adults), and also a good safety profile. The treatment of GHD in adults seems less effective through these options. The growth hormones are injectables. This means even a once-a-day dose will not ensure compliance as it is inconvenient to patients. Companies are now focusing on adult GHD, which will enable them to reap revenues from this growing market. The primary focus would be to provide safer and more efficacious products, with improved formulations to reduce the frequency of administration. LG Life Sciences, Althea Technologies, Ambrx Inc., Novo Nordisk and Ipsen are believed to be working on the same method of meeting the unmet need in the market. The global GHD market is heading towards a phase of continuous but slow growth. Genotropin will lose its patent in April 2013 because of which the market growth is lowered.

Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/29579

Scope

The scope of the report includes:

Annualized global growth hormone deficiency market revenues data from 2001 to 2009, forecast for eight years to 2017.
Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are Pegylated growth hormones, Sustained release growth hormones, long acting growth hormones, recombinant growth hormones.
Analysis of the current and future competition in the global growth hormone deficiency market. The key market players covered include Pfizer Inc., LG Life Sciences. Merck Sorono, Novo Nordisk, Ipsen, Althea Technologies, Anbrx Inc.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future growth hormone deficiency market.


Reasons to buy

The report will enhance your decision making capability. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most promising product candidates in the pipeline.
Develop business strategies by understanding the trends shaping and driving the global Growth Hormone Deficiency market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Growth Hormone Deficiency market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidation, investments and strategic partnerships.
Whats the next big thing in the global Growth Hormone Deficiency market landscape? Identify, understand and capitalize.

About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest articles at http://www.marketresearchreports.biz/articles


View our blog at http://medicaltechnologyandinnovation.blogspot.com

Contact Us

Office: State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: [email protected]